echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medicines Company News > Overweighting the best-selling anti-virus variety, Sunshine Pharmaceuticals grabs the second domestic company

    Overweighting the best-selling anti-virus variety, Sunshine Pharmaceuticals grabs the second domestic company

    • Last Update: 2022-05-24
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Recently, Guangdong Sunshine Pharmaceutical Co.
    , Ltd.
    and Yichang Sunshine Yangtze River Pharmaceutical Co.
    , Ltd.
    have entered the "approval" stage for the three types of generic marketing applications of oseltamivir phosphate dry suspension, which is expected to usher in good news
    .
    Oseltamivir is a large variety of systemic antiviral drugs.
    At present, Yichang Dongguang Changjiang Pharmaceutical Co.
    , Ltd.
    is still the leading enterprise of this variety
    .
     
    Figure 1: Approval of Oseltamivir Phosphate Dry Suspension
    Source: NMPA official website
     
    Table 1: TOP5 varieties of systemic antiviral drugs in 2021E retail market
    Source: Minet.
    com China's urban physical pharmacy terminal competition pattern
     
    Oseltamivir is one of the major varieties of systemic antiviral drugs.
    Under the impact of the epidemic, the prevalence of influenza has declined, and the sales of this variety have also declined rapidly.
    In 2021, the sales of oseltamivir at the physical pharmacy terminals in urban China are expected to be only 20% .
    About 300 million yuan, but the ranking is still firmly in TOP2, and it is expected to wait for the opportunity
    .
     
    Figure 2: Approval of oseltamivir preparations
    Source: new version database of Minet
     
    The domestically produced Oseltamivir Phosphate Capsules have entered the market blowout period in the past two years, and 9 domestic pharmaceutical companies have been approved; Oseltamivir Phosphate Granules are still the exclusive product of Yichang Dongguang Changjiang Pharmaceutical Co.
    , Ltd.
    ; Chengdu Bite Pharmaceutical won the first domestic imitation of oseltamivir phosphate dry suspension in March this year.
    Judging from the current situation, the second domestic company will be included in the bag of HEC
    .
     
    Sunshine Pharma’s layout in oseltamivir is also gradually expanding.
    At present, in addition to capsules and granules, dry suspensions are also about to be approved.
    The company also submitted oseltamivir phosphate sustained-release tablets 2.
    2 new drugs earlier.
    The clinical application is currently under review and approval
    .
     
      Source: NMPA official website, Minet database
     
      Note: Minet.
    com China's urban physical pharmacy terminal competition pattern database is an enlarged version of the urban physical pharmacy database that covers 297 cities and above cities nationwide (excluding county and rural physical pharmacies) and continuously monitors all categories
    .
    The above sales are calculated based on the average retail price of the product in the terminal
    .
    The statistics are as of April 11.
    If there are any mistakes or omissions, please correct me
    .
      Recently, Guangdong Sunshine Pharmaceutical Co.
    , Ltd.
    and Yichang Sunshine Yangtze River Pharmaceutical Co.
    , Ltd.
    have entered the "approval" stage for the three types of generic marketing applications of oseltamivir phosphate dry suspension, which is expected to usher in good news
    .
    Oseltamivir is a large variety of systemic antiviral drugs.
    At present, Yichang Dongguang Changjiang Pharmaceutical Co.
    , Ltd.
    is still the leading enterprise of this variety
    .
     
      Figure 1: Approval of Oseltamivir Phosphate Dry Suspension
      Source: NMPA official website
     
      Table 1: TOP5 varieties of systemic antiviral drugs in 2021E retail market
      Source: Minet.
    com China's urban physical pharmacy terminal competition pattern
     
      Oseltamivir is one of the major varieties of systemic antiviral drugs.
    Under the impact of the epidemic, the prevalence of influenza has declined, and the sales of this variety have also declined rapidly.
    In 2021, the sales of oseltamivir at the physical pharmacy terminals in urban China are expected to be only 20% .
    About 300 million yuan, but the ranking is still firmly in TOP2, and it is expected to wait for the opportunity
    .
     
      Figure 2: Approval of oseltamivir preparations
      Source: new version database of Minet
     
      The domestically produced Oseltamivir Phosphate Capsules have entered the market blowout period in the past two years, and 9 domestic pharmaceutical companies have been approved; Oseltamivir Phosphate Granules are still the exclusive product of Yichang Dongguang Changjiang Pharmaceutical Co.
    , Ltd.
    ; Chengdu Bite Pharmaceutical won the first domestic imitation of oseltamivir phosphate dry suspension in March this year.
    Judging from the current situation, the second domestic company will be included in the bag of HEC
    .
     
      Sunshine Pharma’s layout in oseltamivir is also gradually expanding.
    At present, in addition to capsules and granules, dry suspensions are also about to be approved.
    The company also submitted oseltamivir phosphate sustained-release tablets 2.
    2 new drugs earlier.
    The clinical application is currently under review and approval
    .
     
      Source: NMPA official website, Minet database
     
      Note: Minet.
    com China's urban physical pharmacy terminal competition pattern database is an enlarged version of the urban physical pharmacy database that covers 297 cities and above cities nationwide (excluding county and rural physical pharmacies) and continuously monitors all categories
    .
    The above sales are calculated based on the average retail price of the product in the terminal
    .
    The statistics are as of April 11.
    If there are any mistakes or omissions, please correct me
    .
      Recently, Guangdong Sunshine Pharmaceutical Co.
    , Ltd.
    and Yichang Sunshine Yangtze River Pharmaceutical Co.
    , Ltd.
    have entered the "approval" stage for the three types of generic marketing applications of oseltamivir phosphate dry suspension, which is expected to usher in good news
    .
    Oseltamivir is a large variety of systemic antiviral drugs.
    At present, Yichang Dongguang Changjiang Pharmaceutical Co.
    , Ltd.
    is still the leading enterprise of this variety
    .
     
      Figure 1: Approval of Oseltamivir Phosphate Dry Suspension
      Source: NMPA official website
     
      Table 1: TOP5 varieties of systemic antiviral drugs in 2021E retail market
      Source: Minet.
    com China's urban physical pharmacy terminal competition pattern
     
      Oseltamivir is one of the major varieties of systemic antiviral drugs.
    Under the impact of the epidemic, the prevalence of influenza has declined, and the sales of this variety have also declined rapidly.
    In 2021, the sales of oseltamivir at the physical pharmacy terminals in urban China are expected to be only 20% .
    About 300 million yuan, but the ranking is still firmly in TOP2, and it is expected to wait for the opportunity
    .
    pharmacy pharmacy pharmacy
     
      Figure 2: Approval of oseltamivir preparations
      Source: new version database of Minet
     
      The domestically produced Oseltamivir Phosphate Capsules have entered the market blowout period in the past two years, and 9 domestic pharmaceutical companies have been approved; Oseltamivir Phosphate Granules are still the exclusive product of Yichang Dongguang Changjiang Pharmaceutical Co.
    , Ltd.
    ; Chengdu Bite Pharmaceutical won the first domestic imitation of oseltamivir phosphate dry suspension in March this year.
    Judging from the current situation, the second domestic company will be included in the bag of HEC
    .
     
      Sunshine Pharma’s layout in oseltamivir is also gradually expanding.
    At present, in addition to capsules and granules, dry suspensions are also about to be approved.
    The company also submitted oseltamivir phosphate sustained-release tablets 2.
    2 new drugs earlier.
    The clinical application is currently under review and approval
    .
     
      Source: NMPA official website, Minet database
     
      Note: Minet.
    com China's urban physical pharmacy terminal competition pattern database is an enlarged version of the urban physical pharmacy database that covers 297 cities and above cities nationwide (excluding county and rural physical pharmacies) and continuously monitors all categories
    .
    The above sales are calculated based on the average retail price of the product in the terminal
    .
    The statistics are as of April 11.
    If there are any mistakes or omissions, please correct me
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.